Clinical Scenarios for Long-term Monitoring of Epileptic Seizures With a Wearable Biopotential Technology

NCT ID: NCT04284072

Last Updated: 2022-11-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

496 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-22

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinically validate a biopotential and motion recording wearable device (Byteflies Sensor Dot) for detection of epileptic seizures in the epilepsy monitoring unit (EMU) and at home.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects with refractory epilepsy who are admitted to the Epilepsy Monitoring Unit (EMU) for clinically-indicated long-term video-EEG assessment will be simultaneously monitored with Sensor Dots to record electroencephalographic (EEG), electrocardiographic (ECG), electromyographic (EMG), and motion signals.

A subset of subjects will continue using Sensor Dot devices at home (Home Phase) after completing the EMU Phase.

The data recorded by Sensor Dots will be used to: 1) annotate epileptic seizures, which will be compared to the annotations made as part of routine EMU monitoring and seizure diaries kept at home, and 2) to develop seizure detection algorithms. The data collected as part of this study will not be used to influence clinical decision making.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All subjects

Single arm study with a device intervention for epileptic seizure monitoring in subjects with refractory focal impaired awareness, tonic-clonic, and/or typical absence seizures.

Group Type EXPERIMENTAL

Sensor Dot

Intervention Type DEVICE

Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sensor Dot

Multimodal (EEG, ECG, EMG and motion) seizure monitoring with Sensor Dot to complement EMU-based video-EEG monitoring (EMU Phase), and optional home-based seizure diary logging (Home Phase).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects (4+ years old) with refractory epilepsy who are admitted to the hospital for clinically-indicated long-term video-EEG assessment or presurgical evaluation, and a high likelihood of experiencing seizures during the EMU Phase
* For subjects continuing into the Home Phase: successful recording of their habitual seizures with Sensor Dot during the EMU Phase
* For subjects continuing into the Home Phase: the ability to keep an e-diary

Exclusion Criteria

* Known allergies to any of the biopotential electrodes or adhesives used as part of the study protocol
* Having an implanted device, such as (but not limited to) a pacemaker, cardioverter defibrillator (ICD), and/or neural stimulation device because Sensor Dot contains magnets that could interfere with the operation of these devices
* Women who are pregnant
Minimum Eligible Age

4 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Freiburg University

UNKNOWN

Sponsor Role collaborator

King's College London

OTHER

Sponsor Role collaborator

Oxford University Hospitals NHS Trust

OTHER

Sponsor Role collaborator

University of Coimbra

OTHER

Sponsor Role collaborator

Karolinska Institutet

OTHER

Sponsor Role collaborator

RWTH Aachen University

OTHER

Sponsor Role collaborator

UCB Pharma

INDUSTRY

Sponsor Role collaborator

Byteflies

INDUSTRY

Sponsor Role collaborator

Helpilepsy

UNKNOWN

Sponsor Role collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wim Van Paesschen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

UZ Leuven and KU Leuven

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospitals Leuven, department of Neurology

Leuven, , Belgium

Site Status

Department of Epileptology and Neurology

Aachen, , Germany

Site Status

Epilepsy Center, University Medical Center, Freiburg University

Freiburg im Breisgau, , Germany

Site Status

Division of Neurology, Coimbra University Hospital

Coimbra, , Portugal

Site Status

Department of Clinical Neuroscience, Karolinska Institute

Stockholm, , Sweden

Site Status

Division of Neuroscience, King's College London

London, , United Kingdom

Site Status

Nuffield Department of Clinical Neurosciences, Oxford University Hospital

Oxford, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Germany Portugal Sweden United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshe SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475-82. doi: 10.1111/epi.12550. Epub 2014 Apr 14.

Reference Type BACKGROUND
PMID: 24730690 (View on PubMed)

Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol. 2003 Apr;16(2):165-70. doi: 10.1097/01.wco.0000063766.15877.8e.

Reference Type BACKGROUND
PMID: 12644744 (View on PubMed)

Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000 Feb 3;342(5):314-9. doi: 10.1056/NEJM200002033420503.

Reference Type BACKGROUND
PMID: 10660394 (View on PubMed)

Elger CE, Hoppe C. Diagnostic challenges in epilepsy: seizure under-reporting and seizure detection. Lancet Neurol. 2018 Mar;17(3):279-288. doi: 10.1016/S1474-4422(18)30038-3.

Reference Type BACKGROUND
PMID: 29452687 (View on PubMed)

Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. Arch Neurol. 2007 Nov;64(11):1595-9. doi: 10.1001/archneur.64.11.1595.

Reference Type BACKGROUND
PMID: 17998441 (View on PubMed)

Kurada AV, Srinivasan T, Hammond S, Ulate-Campos A, Bidwell J. Seizure detection devices for use in antiseizure medication clinical trials: A systematic review. Seizure. 2019 Mar;66:61-69. doi: 10.1016/j.seizure.2019.02.007. Epub 2019 Feb 13.

Reference Type BACKGROUND
PMID: 30802844 (View on PubMed)

Bidwell J, Khuwatsamrit T, Askew B, Ehrenberg JA, Helmers S. Seizure reporting technologies for epilepsy treatment: A review of clinical information needs and supporting technologies. Seizure. 2015 Nov;32:109-17. doi: 10.1016/j.seizure.2015.09.006. Epub 2015 Sep 18.

Reference Type BACKGROUND
PMID: 26552573 (View on PubMed)

Beniczky S, Ryvlin P. Standards for testing and clinical validation of seizure detection devices. Epilepsia. 2018 Jun;59 Suppl 1:9-13. doi: 10.1111/epi.14049.

Reference Type BACKGROUND
PMID: 29873827 (View on PubMed)

Szabo CA, Morgan LC, Karkar KM, Leary LD, Lie OV, Girouard M, Cavazos JE. Electromyography-based seizure detector: Preliminary results comparing a generalized tonic-clonic seizure detection algorithm to video-EEG recordings. Epilepsia. 2015 Sep;56(9):1432-7. doi: 10.1111/epi.13083. Epub 2015 Jul 20.

Reference Type BACKGROUND
PMID: 26190150 (View on PubMed)

Beniczky S, Conradsen I, Wolf P. Detection of convulsive seizures using surface electromyography. Epilepsia. 2018 Jun;59 Suppl 1:23-29. doi: 10.1111/epi.14048.

Reference Type BACKGROUND
PMID: 29873829 (View on PubMed)

Beniczky S, Polster T, Kjaer TW, Hjalgrim H. Detection of generalized tonic-clonic seizures by a wireless wrist accelerometer: a prospective, multicenter study. Epilepsia. 2013 Apr;54(4):e58-61. doi: 10.1111/epi.12120. Epub 2013 Feb 8.

Reference Type BACKGROUND
PMID: 23398578 (View on PubMed)

Kjaer TW, Sorensen HBD, Groenborg S, Pedersen CR, Duun-Henriksen J. Detection of Paroxysms in Long-Term, Single-Channel EEG-Monitoring of Patients with Typical Absence Seizures. IEEE J Transl Eng Health Med. 2017 Jan 9;5:2000108. doi: 10.1109/JTEHM.2017.2649491. eCollection 2017.

Reference Type BACKGROUND
PMID: 29018634 (View on PubMed)

Zibrandtsen IC, Kidmose P, Christensen CB, Kjaer TW. Ear-EEG detects ictal and interictal abnormalities in focal and generalized epilepsy - A comparison with scalp EEG monitoring. Clin Neurophysiol. 2017 Dec;128(12):2454-2461. doi: 10.1016/j.clinph.2017.09.115. Epub 2017 Oct 12.

Reference Type BACKGROUND
PMID: 29096220 (View on PubMed)

Gu Y, Cleeren E, Dan J, Claes K, Van Paesschen W, Van Huffel S, Hunyadi B. Comparison between Scalp EEG and Behind-the-Ear EEG for Development of a Wearable Seizure Detection System for Patients with Focal Epilepsy. Sensors (Basel). 2017 Dec 23;18(1):29. doi: 10.3390/s18010029.

Reference Type BACKGROUND
PMID: 29295522 (View on PubMed)

Dan J, Weckhuysen D, Cleeren E, Van Paesschen W, Vandendriessche B. Technical validation of Sensor Dot: a wearable for ambulatory monitoring of epileptic seizures. 2nd International Congress on mobile devices and seizure detection in epilepsy; Lausanne, Switzerland, 2019.

Reference Type BACKGROUND

Seeck M, Koessler L, Bast T, Leijten F, Michel C, Baumgartner C, He B, Beniczky S. The standardized EEG electrode array of the IFCN. Clin Neurophysiol. 2017 Oct;128(10):2070-2077. doi: 10.1016/j.clinph.2017.06.254. Epub 2017 Jul 17.

Reference Type BACKGROUND
PMID: 28778476 (View on PubMed)

Macea J, Heremans ERM, Proost R, De Vos M, Van Paesschen W. Automated Sleep Staging in Epilepsy Using Deep Learning on Standard Electroencephalogram and Wearable Data. J Sleep Res. 2025 Oct;34(5):e70061. doi: 10.1111/jsr.70061. Epub 2025 Apr 3.

Reference Type DERIVED
PMID: 40176726 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://www.eithealth.eu/seizeit2

EIT Health website referring to our SeizeIT2 project

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

S63631

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Microelectrodes in Epilepsy
NCT05200455 COMPLETED NA
EEG@HOME (Phase 1 of the Project)
NCT02408666 COMPLETED NA
ECV - Epihunter Clinical Validation
NCT04615442 COMPLETED NA